Harbinger Health

News

Beeline Medicines, Oricell, Terremoto, Harbinger, Neomorph, Adcendo, and STORM all closed impressive financing rounds in the last week.

News

Shares in uniQure have rocketed this morning, as it emerges that the FDA will not require it to run a new trial of Huntington's gene therapy AMT-130.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.